Kirk A. Findlay
Impact in
- Biological Psychiatry top 5%
- Physiology top 2%
- Alzheimer's disease research and treatments
Papers in
-
- Escherichia coli research studies 2
- Virology 1
- HIV Research and Treatment 1
- Co-authors
- Todd E. GoldeMary Jo WickStaffan NormarkJohn D. PfeiferRichard RobertsMichael P. MurphyEdward H. KooRong Wang
- Journals
- Nature (2 papers)The Journal of Immunology (1 paper)Immunology (1 paper)Infection and Immunity (1 paper)Journal of Biological Chemistry (1 paper)
- Partner nations
- United StatesUnited KingdomCanada
In The Last Decade
Kirk A. Findlay
12 papers receiving 2.1k citations
Hit Papers
Peers
Comparison fields: 5 of 99
- Biological Psychiatry 102
- Physiology 1.0k
- Pharmacology 532
- Neurology 250
- Immunology 562
Countries citing papers authored by Kirk A. Findlay
This map shows the geographic impact of Kirk A. Findlay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kirk A. Findlay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kirk A. Findlay more than expected).
Fields of papers citing papers by Kirk A. Findlay
This network shows the impact of papers produced by Kirk A. Findlay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kirk A. Findlay. The network helps show where Kirk A. Findlay may publish in the future.
Co-authors
The 25 scholars most cited alongside Kirk A. Findlay, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2010 | 1 | |
| 2 | 2002 | 75 | |
| 3 | A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity Hit paper breakdown → | 2001 | 1103 |
| 4 | Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney. | 2001 | 87 |
| 5 | 2000 | 92 | |
| 6 | 2000 | 94 | |
| 7 | 1998 | 54 | |
| 8 | 1996 | 18 | |
| 9 | Phagocytic processing of bacterial antigens for class I MHC presentation to T cells Hit paper breakdown → | 1993 | 526 |
| 10 | 1993 | 32 | |
| 11 | 1992 | 12 | |
| 12 | 1992 | 102 |
About Kirk A. Findlay
Kirk A. Findlay is a scholar working on Endocrinology, Virology, Immunology, Pharmacology and Physiology, having authored 12 papers that have together received 2.2k indexed citations. Recurring topics across this work include Alzheimer's disease research and treatments (4 papers), Immunotherapy and Immune Responses (4 papers), Escherichia coli research studies (2 papers), Immune Cell Function and Interaction (2 papers), Inflammatory mediators and NSAID effects (2 papers), Neurological diseases and metabolism (1 paper), Autoimmune Bullous Skin Diseases (1 paper) and HIV Research and Treatment (1 paper). The work is most often cited by research in Biological Psychiatry (102 citations), Physiology (1.0k citations), Pharmacology (532 citations), Neurology (250 citations) and Immunology (562 citations). Kirk A. Findlay has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Todd E. Golde, Mary Jo Wick, Staffan Normark, John D. Pfeifer, Richard Roberts, Michael P. Murphy, Edward H. Koo, Rong Wang, Sarah A. Sagi and David E. Kang. Their work appears in journals such as Nature, The Journal of Immunology, Immunology, Infection and Immunity and Journal of Biological Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.